This guideline document lays out the indicators for monitoring the 2016 Political Declaration on ending AIDS. The Global AIDS Monitoring (GAM) process has been often referenced as a benchmark for successful international accountability mechanisms.
In the context of an unprecedented event such as the COVID-19 pandemic, at present, the effectiveness of stringent social distancing and international traffic-related measures in decreasing the rate of spread of SARS-CoV-2, and related mortality, is inferred from empiric observations of their applic...ation in countries experiencing different transmission scenarios (e.g., Australia, China, Germany, Italy, New Zealand, and Spain). Such observations are consistent with and corroborated by mathematical models.
more
The content of the tool has been updated to reflect new WHO technical guidance and new evidence on both COVID-19 pandemic and mass gatherings, as well as feedback from end-users. This revision of the risk assessment tool was developed and reviewed by the WHO Mass Gathering Technical Expert Group wit...h input from WHO area-specific technical teams. The expanded tool includes eight tabs: 1. Instructions; 2. Assessment Overview; 3. Decision Tree; 4. Risk Evaluation; 5. Risk Mitigation; 6. Decision Matrix; 7. Risk Communication; and 8. Reviewer Sign Off. There as an additional tab with a glossary and list of abbreviations.
more
Severe acute respiratory infections treatment centre: practical manual to set up and manage a SARI treatment centre and a SARI screening facility in health care facilities
Global procurement for COVID-19 vaccines
The WHO COVID-19 Essential Supplies Forecasting Tool (COVID-19-ESFT) is meant to help countries forecast essential supplies for their COVID-19 response including personal protective equipment (e.g., masks and gloves), biomedical equipment for case management (e.g., ventilators and oxygen concentrato...rs), diagnostic reagents and equipment, essential drugs for supportive care, and consumable medical supplies.
The tool is best suited for estimating essential supply needs over a short time period (12 weeks or fewer) but can be used for longer.
COVID-19-ESFT does not quantify or account for resources already available locally or those pending delivery. When using the ESFT to inform procurement, we recommend factoring in resources already available locally and only including the additional resources required in the forecast.
This tool is updated regularly so users should monitor the website for the latest release version.
more
Whole-genome sequencing (WGS) provides a vast amount of information and the highest possible resolution for pathogen subtyping. The application of WGS for global surveillance can provide information on the early emergence and spread of AMR and further inform timely policy development on AMR control.... Sequencing data emanating from AMR surveillance may provide key information to guide the development of rapid diagnostic tools for better and more rapid characterization of AMR, and thus complement phenotypic methods. This document addresses the applications of WGS for AMR surveillance, including the benefits and limitations of current WGS technologies
more
The document "Priority medical devices list for the COVID-19 response and associated technical specifications" complements this guideline.
This document provides interim guidance on the quality, performance characteristics and related standards of personal protective equipment (PPE) to be used i...n the context of COVID-19. This includes WHO Priority Medical Devices, specifically: surgical masks, non-surgical masks, gloves, googles, face shields, gowns and N95 masks. It is intended for procurement agencies, occupational health departments, infection prevention and control departments or focal points, health facility administrators, biomedical and materials engineering, PPE manufacturers and public health authorities at both national and facility levels.
more
WHO technical advisory group on behavioural insights and sciences for health, meeting report, 15 October 2020
This document is part three in a series of explainers on vaccine development and distribution. Part one focused on how vaccines work to protect our bodies from disease-carrying germs. Part two focused on the ingredients in a vaccine and the three clinical trial phases.
This document outlines the... next part of the vaccine journey: the steps from completing the clinical trial phases through to distribution.
more
Available in English, French, Spanish, Chinese, Russian and Arabic
https://apps.who.int/iris/handle/10665/337832
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...st issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/361720
more
Guidelines on the management of chronic pain in children, developing and implementing national and local policies for pain management and protocols in children, implementing national and local regulations for pain management in children, pain management and protocols
Prepared by the Independent Panel for Pandemic Preparedness and Response for the WHO Executive Board, January 2021
“The world was not as prepared as it should have been, and it must do better,” concludes a WHO panel reviewing the pandemic response "
Mobile vaccination teams visiting long-term care homes will have an important role in providing vaccination coverage for some of the most vulnerable population sub-groups. However, based on the experiences of German mobile diagnostic teams during the first COVID-19 pandemic w...ave, the deployment of mobile vaccination teams to care homes for older adults and people with disabilities is expected to raise various ethical challenges.
more